AYI, INHX, IDIX - CRWESelect.com Stock News! Acuity Brands, Inhibitex, Idenix Pharmaceuticals (Video Included Inside)

FOR IMMEDIATE RELEASE
(Free-Press-Release.com) January 9, 2012 -- To view video, and read the full article visit URL http://crweselect.com/28107/stock-alerts/ayi-inhx-idix-crweselectcom-stock-news-acuity-brands-inhibitex-idenix-pharmaceuticals-video-included-inside/

Acuity Brands, Inc. (NYSE:AYI)

AYI announced today fiscal 2012 first quarter net sales of $474.3 million, an increase of $49.3 million, or approximately 12 percent, compared with the year-ago period. Net income for the first quarter of fiscal 2012 was $29.9 million compared with $24.4 million for the year-ago period, an increase of 23 percent. Diluted earnings per share for the first quarter of fiscal 2012 increased to $0.70 compared with $0.56 reported for the prior-year period. Included in the results for the first quarter of fiscal 2012 was a $2.7 million pre-tax special charge associated with actions to streamline the organization through the realignment of responsibilities within various selling, distribution, and administrative departments. Excluding the special charge, fiscal 2012 first quarter adjusted diluted EPS were $0.74, an increase of 32 percent compared with the year-ago period.

AYI is a North American market leader and one of the world’s leading providers of lighting solutions for both indoor and outdoor applications.

For more information about AYI please visit http://www.acuitybrands.com

****

Inhibitex, Inc. (NASDAQ:INHX)

According to a definitive agreement between the companies, Bristol-Myers Squibb will acquire Inhibitex Incorporated - symbol INHX - for $26.00 per share in cash pursuant to a cash tender offer and second step merger.

INHX, a biopharmaceutical company, focuses on the development of differentiated anti-infective products to prevent or treat serious infections. It primarily focuses to treat shingles caused by the varicella zoster virus and chronic infections caused by hepatitis C virus (HCV).

For more information about INHX please visit http://www.inhibitex.com/

****

Idenix Pharmaceuticals, Inc. (NASDAQ:IDIX)

IDIX announced today interim data from a 12-week phase IIb clinical trial of IDX184, the Company's lead product candidate for the treatment of hepatitis C virus (HCV) infection. IDX184, a pan-genotypic oral nucleotide polymerase inhibitor, has demonstrated a high barrier to resistance in vitro and potent antiviral activity in both preclinical and clinical studies.

In addition, IDIX announced today the advancement of its hepatitis C virus (HCV) development pipeline. . Idenix announced today the initiation of a phase I clinical trial of the Company's NS5A inhibitor, IDX719. Further, the Company has selected two additional nucleotide inhibitors, IDX19368 and c, as potential clinical candidates. The Company anticipates Investigational New Drug (IND) filings in mid-2012.

IDIX, headquartered in Cambridge, Massachusetts , is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases. Idenix's current focus is on the treatment of patients with hepatitis C infection.

For more information about IDIX please visit http://www.idenix.com/

To read the full article visit URL http://crweselect.com/28107/stock-alerts/ayi-inhx-idix-crweselectcom-stock-news-acuity-brands-inhibitex-idenix-pharmaceuticals-video-included-inside/

****************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWESelect.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer( http://crweselect.com/disclaimer/) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWESelect.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock.Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

AYIcrweselect0109
INHXcrweselect0109
IDIXcrweselect0109

Acuity Brands     AYI     bristol-myers squibb     Hepatitis C Virus     Idenix Pharmaceuticals     IDIX     Inhibitex     INHX